| Luye Pharma Switzerland AG - Rivasur zweimal wöchentlich 9,5 mg/24 Stunden, Transdermales Pflaster | | 68897 | | 02 | | Rivasur zweimal wöchentlich 9,5 mg/24 Stunden | | Transdermales Pflaster | | N06DA03 | | Rivastigmin | | 13.02.2024 | | |
| | Composition | | I) (Transdermales Pflaster): rivastigminum 51.84 mg, E 307, 2-ethylhexylis acrylatis et vinylis acetatis polymerisatum, butylis methacrylatis et methylis methacrylatis polymerisatum, polyisobutylenum, polybutylenum, Trägermaterial: poly(ethylenis terephthalas), polyethylenum, Drucktinte: Blau, ad praeparationem pro 21.6 cm², cum liberatione 9.5 mg/24h.
II) (Abdeckpflaster): acrylates et vinylis acetatis polymerisatum, Trägermaterial: polyesterum, ad praeparationem pro 46.7 cm². | | Packungsbestandteile | | I | | Timbre transdermique | | | | Principe actif | Concentr. |
|---|
| (Transdermales Pflaster): Rivastigminum | 51.84 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| 2-ethylhexylis Acrylatis | | | | Ad Praeparationem | 21.6 cm | | | Blau | | Drucktinte | | Butylis Methacrylatis | | | | Cum Liberatione | 9.5mg / 24h | | | E 307 | | | | Methylis Methacrylatis Polymerisatum | | | | Poly(Ethylenis Terephthalas) | | Trägermaterial | | Polybutylenum | | | | Polyethylène | | | | Polyisobutylenum | | | | Vinylis Acetatis Polymerisatum | | |
|
| II | | Timbre transdermique | | | | | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| (Abdeckpflaster): Acrylates | | | | Ad Praeparationem | 46.7 cm | | | Polyesterum | | Trägermaterial | | Vinylis Acetatis Polymerisatum | | |
|
| |
|
